Kimberly Tarnai
Medical · Staunton, VANPI 1285296111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 612 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 24.4% of the total. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 612 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$980
- Otsuka America Pharmaceutical, Inc.$956
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$912
- Lundbeck LLC$635
- Neurocrine Biosciences, Inc.$532
- plus $4K from 27 others
What the payments were for
- Food & beverage$10,027100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,074 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 31 | $51,420 |
| Invega SustennaPaliperidone Palmitate | 12 | $45,821 |
| TrintellixVortioxetine Hydrobromide | 29 | $14,595 |
| Aripiprazole | 106 | $5,523 |
| Eszopiclone | 57 | $2,995 |
| Duloxetine Hcl | 69 | $2,193 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 64 | $1,889 |
| Olanzapine | 73 | $1,833 |
| Bupropion XlBupropion Hcl | 111 | $1,744 |
| Oxcarbazepine | 62 | $1,548 |
| Divalproex Sodium ErDivalproex Sodium | 49 | $1,395 |
| Buspirone Hcl | 118 | $1,027 |
| Gabapentin | 79 | $996 |
| Divalproex Sodium | 42 | $901 |
| Lamotrigine | 84 | $669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $912 | $51,42031 claims |
| Johnson & JohnsonInvega Sustenna | $405 | $45,82112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $465 | $14,59529 claims |
| Lilly USA, LLCOlanzapine | $31 | $1,83373 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $41389 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Staunton
- Kelli CashStaunton$12K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.